Tesamorelin for the Potential Treatment of NASH

Non-alcoholic fatty liver disease (NAFLD) is a term that defines a continuum of different liver diseases. The early stage starts with non-alcoholic fatty liver (NAFL), which may progress to chronic liver inflammation (non-alcoholic steatohepatitis [NASH]), fibrosis, cirrhosis and hepatocellular carcinoma (HCC)12, 1, 2. NAFLD is the most common chronic liver condition. It is estimated that approximately 20 to 25% of adults in many countries (United States, France, Germany, Italy, Spain, United Kingdom and Canada) have NAFLD3, 4. The prevalence of NASH is between 2.5 to 5% in those countries. Most people with NAFLD simply have fatty liver. NAFLD pathogenesis includes many contributing factors like lipogenesis and lipotoxicity, inflammation, insulin resistance and oxidative stress2.